Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3001–3024 of 8,385 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: serum sample Clear all

Conditions: Ulcerative Colitis
Interventions: Tacrolimus, Vedolizumab, Placebo; Drug · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Autism Spectrum Disorder, Atopy
Interventions: Omalizumab Injection [Xolair]; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 30 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer
Interventions: pTVG-HP, Nivolumab, GM-CSF; Biological · Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: aldesleukin, ipilimumab; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
Interventions: Bone Marrow Aspiration and Biopsy, Computed Tomography, Echocardiography Test, Lenalidomide, Lumbar Puncture, Magnetic Resonance Imaging, Methotrexate, Nivolumab, Positron Emission Tomography, Rituximab, Ultrasound Imaging; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 56
States / cities: Los Angeles, California • San Francisco, California • Coral Gables, Florida + 43 more

Conditions: Rheumatoid Arthritis, Chronic Hepatitis B
Interventions: Abatacept, Placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Melanoma
Interventions: Doxycycline, Ipilimumab, Temozolomide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS
Interventions: VS-7375, cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction); Drug
Lead sponsor: Verastem, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 27
States / cities: Los Angeles, California • Coral Springs, Florida • Jacksonville, Florida + 21 more

Conditions: Multiple Sclerosis
Interventions: Tysabri® (natalizumab); Drug
Lead sponsor: Biogen; Industry
Eligibility: Not listed
Enrollment: 1,096 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 11
States / cities: Aurora, Colorado • Atlanta, Georgia • Cullman, Georgia + 8 more

Conditions: Metastatic Uveal Melanoma
Interventions: Nivolumab, Relatlimab; Drug
Lead sponsor: Jose Lutzky, MD; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Radiation Retinopathy
Interventions: ranibizumab 2.0 mg; Drug
Lead sponsor: The New York Eye Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra
Interventions: Sitravatinib, Nivolumab, Pembrolizumab, Enfortumab vedotin; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 36
States / cities: Tucson, Arizona • Irvine, California • Aurora, Colorado + 30 more

Conditions: Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma, Melanoma
Interventions: Nivolumab, Nivolumab + Relatlimab, Ipilimumab; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer
Interventions: Atezolizumab, Placebo, Doxorubicin, Cyclophosphamide, Paclitaxel, Trastuzumab, Pertuzumab, Trastuzumab Emtansine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Kansas City, Missouri • New York, New York • Nashville, Tennessee

Conditions: Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Interventions: NKTR-255, Cetuximab; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 6
States / cities: San Diego, California • San Francisco, California • Minneapolis, Minnesota + 3 more

Conditions: Urticaria Chronic
Interventions: Omalizumab; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Anemia, Iron Deficiency
Interventions: Intrinsic Hepcidin IDx™ Test; Diagnostic Test
Lead sponsor: Intrinsic LifeSciences, LLC; Industry
Eligibility: 11 Years and older
Enrollment: 494 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ischemic Central Retinal Vein Occlusion
Interventions: Ranibizumab (Lucentis); Drug
Lead sponsor: Greater Houston Retina Research; Other
Eligibility: 19 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Kidney Disease Mineral and Bone Disorder
Interventions: Phosphorus Absorption Test; Other
Lead sponsor: Purdue University; Other
Eligibility: 30 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Leukapheresis, Cyclophosphamide, Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA, Quality of Life (QoL) Questionnaires, Bone Marrow Biopsy, Biospecimen Collection, Fludarabine, Radiographic imaging; Procedure · Drug · Biological + 1 more
Lead sponsor: Thomas Martin, MD; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2043
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Colorectal Neoplasms
Interventions: Cetuximab; Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 744 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 29
States / cities: Bakersfield, California • Los Angeles, California • Denver, Colorado + 26 more

Conditions: Refractory Solid Tumors in Children
Interventions: Irinotecan, Vincristine, Temozolomide, Bevacizumab; Drug
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 12 Months to 20 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Pembrolizumab, Ipilimumab, Placebo; Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 568 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 25
States / cities: Phoenix, Arizona • Burbank, California • Monterey, California + 21 more

Conditions: Cutis Laxa Facialis, Xeroderma
Interventions: HydraFacial Syndeo System, ReGen-GF, HydraFacial Elite MD System; Device · Drug
Lead sponsor: Austin Institute for Clinical Research; Network
Eligibility: 30 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Houston, Texas • Pflugerville, Texas

Search by objective public record fields.

Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UC

Xolair Interventional Study in ASD Patients With Comorbid Atopy

pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer

Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background

Doxycycline, Temozolomide and Ipilimumab in Melanoma

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

JC-Virus (JCV) Antibody Program

Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU)

Serum Hepcidin Immunoassay - Laboratory to Marketplace

Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion

Phosphorus Absorption in Healthy Adults and in Patients With Moderate Chronic Kidney Disease

CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma

A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer

A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin

Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)

Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types.